Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-HCC01: Rilvegostomig + bevacizumab ± tremelimumab in first-line advanced hepatocellular carcinoma
2024-518210-81-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of rilvegostomig in hepatocellular carcinoma (HCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall Survival. Planned start Sep 2025; status: authorised.
02
Drugs
rilvegostomig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-518210-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518210-81-00.